Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Reports Trial Data from PD-1 Drug in Three Separate Indications

publication date: Jun 3, 2020

At the virtual ASCO conference, Suzhou Innovent announced clinical results from three trials of its PD-1 drug, Tyvyt®:

• In a Phase II trial among patients with relapsed or refractory classic Hodgkin's lymphoma, the ORR was 85.4% and complete response (CR) 42.7%;
• In a two-year study among patients with relapsed or refractory extranodal NK/T-cell lymphoma, the ORR was 67.9% and the CR 14.3%;
• As a second-line treatment in patients with esophageal squamous cell carcinoma, the 12-month survival rates were 37.4% in the Tyvyt cohort and 21.4% in the chemotherapy group.

In 2018, Tyvyt was approved for use in China as a third-line treatment for patients with classical Hodgkin's lymphoma. It is currently being tested in 20 clinical trials. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here